Anthony Rusk
Research Subjects
Anthony Rusk has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Chand Khanna
Animal Clinical Investigation, LLC, Columbia, Maryland and
2 shared publicationsJack Henkin
Abbott Laboratories, Abbott Park, Illinois
2 shared publicationsA.I. Sahora
The Oncology Service, LLC , Washington, DC
1 shared publicationC. Khanna
The Oncology Service, LLC , Washington, DC
1 shared publication- Craig Paul Webb
Center for Translational Medicine, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503, USA
1 shared publication - David Cherba
Van Andel Research Institute, Grand Rapids, MI, USA
1 shared publication
Latest Publications
- Open Access
- 1 July 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 158
A multi-site feasibility study for personalized medicine in canines with Osteosarcoma
A successful therapeutic strategy, specifically tailored to the molecular constitution of an individual and their disease, is an ambitious objective of modern medicine. In this report, we highlight a feasibility study in canine osteosarcoma focused on refining the infrastructure and processes required for prospective clinical trials using a series of gene expression-based Personalized Medicine (PMed) algorithms to predict suitable therapies within 5 days of sample receipt. Tumor tissue samples were collected immediately following limb amputation and shipped overnight from veterinary practices. Upon receipt (day 1), RNA was extracted from snap-frozen tissue, with an adjacent H&E section for pathological diagnosis. Samples passing RNA and pathology QC were shipped to a CLIA-certified laboratory for genomic profiling. After mapping of canine probe sets to human genes and normalization against a (normal) reference set, gene level Z-scores were submitted to the PMed algorithms. The resulting PMed report was immediately forwarded to the veterinarians. Upon receipt and review of the PMed report, feedback from the practicing veterinarians was captured. 20 subjects were enrolled over a 5 month period. Tissue from 13 subjects passed both histological and RNA QC and were submitted for genomic analysis and subsequent PMed analysis and report generation. 11 of the 13 samples for which PMed reports were produced were communicated to the veterinarian within the target 5 business days. Of the 7 samples that failed QC, 4 were due to poor RNA quality, whereas 2 were failed following pathological review. Comments from the practicing veterinarians were generally positive and constructive, highlighting a number of areas for improvement, including enhanced education regarding PMed report interpretation, drug availability, affordable pricing and suitable canine dosing. This feasibility trial demonstrated that with the appropriate infrastructure and processes it is possible to perform an in-depth molecular analysis of a patient’s tumor in support of real time therapeutic decision making within 5 days of sample receipt. A number of areas for improvement have been identified that should reduce the level of sample attrition and support clinical decision making.
- 1 July 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 158
Open AccessA multi-site feasibility study for personalized medicine in canines with Osteosarcoma
A successful therapeutic strategy, specifically tailored to the molecular constitution of an individual and their disease, is an ambitious objective of modern medicine. In this report, we highlight a feasibility study in canine osteosarcoma focused on refining the infrastructure and processes required for prospective clinical trials using a series of gene expression-based Personalized Medicine (PMed) algorithms to predict suitable therapies within 5 days of sample receipt. Tumor tissue samples were collected immediately following limb amputation and shipped overnight from veterinary practices. Upon receipt (day 1), RNA was extracted from snap-frozen tissue, with an adjacent H&E section for pathological diagnosis. Samples passing RNA and pathology QC were shipped to a CLIA-certified laboratory for genomic profiling. After mapping of canine probe sets to human genes and normalization against a (normal) reference set, gene level Z-scores were submitted to the PMed algorithms. The resulting PMed report was immediately forwarded to the veterinarians. Upon receipt and review of the PMed report, feedback from the practicing veterinarians was captured. 20 subjects were enrolled over a 5 month period. Tissue from 13 subjects passed both histological and RNA QC and were submitted for genomic analysis and subsequent PMed analysis and report generation. 11 of the 13 samples for which PMed reports were produced were communicated to the veterinarian within the target 5 business days. Of the 7 samples that failed QC, 4 were due to poor RNA quality, whereas 2 were failed following pathological review. Comments from the practicing veterinarians were generally positive and constructive, highlighting a number of areas for improvement, including enhanced education regarding PMed report interpretation, drug availability, affordable pricing and suitable canine dosing. This feasibility trial demonstrated that with the appropriate infrastructure and processes it is possible to perform an in-depth molecular analysis of a patient’s tumor in support of real time therapeutic decision making within 5 days of sample receipt. A number of areas for improvement have been identified that should reduce the level of sample attrition and support clinical decision making.
- Open Access
- 21 July 2012
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 26 (5) , 1169-1176
Prospective Study of Thrombospondin-1 Mimetic Peptides, ABT-510 and ABT-898, in Dogs with Soft Tissue Sarcoma
Background Exposure to anti‐angiogenic thrombospondin‐1 (TSP‐1) mimetic peptides (MPs) has resulted in sporadic anti‐tumor activity in humans and dogs. Hypothesis Novel TSP‐1 MPs formulations will be safe, tolerated, and clinically active in soft tissue sarcoma (STS) in dogs. Animals Sixty‐two client‐owned dogs with measurable STS were enrolled, excluding hemangiosarcoma. Methods A prospective, single agent, multicenter, open‐label study assessing ABT‐510 bolus, ABT‐898 bolus, or ABT‐898 depot formulations of TSP‐1 in dogs. Endpoints included tolerability, antitumor activity, and the assessment of ability of clinical covariates and circulating endothelial cells (CEC) concentration to predict tumor response. Results Two non‐dose‐limiting toxicoses possibly attributed to treatment were observed (keratitis and osteoarthritis). Antitumor activity (10/44 = 23% responses) was observed in study subjects who received treatment for >28 days (n = 44) including both partial (7) and minimal responses (3). Responses were disproportionately seen in dogs receiving ABT‐898 formulations (9/28 = 32%) versus those receiving ABT‐510 (1/16 = 6%; P < .045). Disease stabilization for >84 days was also documented (8/44 = 18%). Slow rates of tumor progression before study entry correlated with anti‐tumor activity in treated dogs, whereas no significant association was found between changes in total CEC concentration and tumor response (P = .28) or time to progression (P = .42). Conclusions and Clinical Importance Safely achieved antitumor activity was documented with TSP‐1 MPs in dogs with STS. The most notable activity was achieved with the ABT‐898 formulations.
- 21 July 2012
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 26 (5) , 1169-1176
Open AccessProspective Study of Thrombospondin-1 Mimetic Peptides, ABT-510 and ABT-898, in Dogs with Soft Tissue Sarcoma
Background Exposure to anti‐angiogenic thrombospondin‐1 (TSP‐1) mimetic peptides (MPs) has resulted in sporadic anti‐tumor activity in humans and dogs. Hypothesis Novel TSP‐1 MPs formulations will be safe, tolerated, and clinically active in soft tissue sarcoma (STS) in dogs. Animals Sixty‐two client‐owned dogs with measurable STS were enrolled, excluding hemangiosarcoma. Methods A prospective, single agent, multicenter, open‐label study assessing ABT‐510 bolus, ABT‐898 bolus, or ABT‐898 depot formulations of TSP‐1 in dogs. Endpoints included tolerability, antitumor activity, and the assessment of ability of clinical covariates and circulating endothelial cells (CEC) concentration to predict tumor response. Results Two non‐dose‐limiting toxicoses possibly attributed to treatment were observed (keratitis and osteoarthritis). Antitumor activity (10/44 = 23% responses) was observed in study subjects who received treatment for >28 days (n = 44) including both partial (7) and minimal responses (3). Responses were disproportionately seen in dogs receiving ABT‐898 formulations (9/28 = 32%) versus those receiving ABT‐510 (1/16 = 6%; P < .045). Disease stabilization for >84 days was also documented (8/44 = 18%). Slow rates of tumor progression before study entry correlated with anti‐tumor activity in treated dogs, whereas no significant association was found between changes in total CEC concentration and tumor response (P = .28) or time to progression (P = .42). Conclusions and Clinical Importance Safely achieved antitumor activity was documented with TSP‐1 MPs in dogs with STS. The most notable activity was achieved with the ABT‐898 formulations.
- Open Access
- 15 December 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (24) , 7456-7464
Cooperative Activity of Cytotoxic Chemotherapy with Antiangiogenic Thrombospondin-I Peptides, ABT-526 in Pet Dogs with Relapsed Lymphoma
Purpose: Thrombospondin-I (TSP-I) is a natural antiangiogenic protein that enhances apoptosis of activated endothelial cells. A modified nonapeptide from TSP-I, ABT-526, has been found to be active in mouse cancer models and in dogs with naturally occurring cancers. To further assist in the development of ABT-526, we report herein on its evaluation in combination with cytotoxic chemotherapy in pet dogs with relapsed non-Hodgkin's lymphoma (NHL).
- 15 December 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (24) , 7456-7464
Open AccessCooperative Activity of Cytotoxic Chemotherapy with Antiangiogenic Thrombospondin-I Peptides, ABT-526 in Pet Dogs with Relapsed Lymphoma
Purpose: Thrombospondin-I (TSP-I) is a natural antiangiogenic protein that enhances apoptosis of activated endothelial cells. A modified nonapeptide from TSP-I, ABT-526, has been found to be active in mouse cancer models and in dogs with naturally occurring cancers. To further assist in the development of ABT-526, we report herein on its evaluation in combination with cytotoxic chemotherapy in pet dogs with relapsed non-Hodgkin's lymphoma (NHL).
- Open Access
- 15 December 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (24) , 7444-7455
Preclinical Evaluation of Antiangiogenic Thrombospondin-1 Peptide Mimetics, ABT-526 and ABT-510, in Companion Dogs with Naturally Occurring Cancers
Purpose: The angiogenic phenotype of malignant cancers has been established as a target for cancer therapy. ABT-526 and ABT-510, two peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth in mice. To guide the clinical development of these drugs, translational studies in dogs with naturally occurring cancers were initiated.
- 15 December 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (24) , 7444-7455
Open AccessPreclinical Evaluation of Antiangiogenic Thrombospondin-1 Peptide Mimetics, ABT-526 and ABT-510, in Companion Dogs with Naturally Occurring Cancers
Purpose: The angiogenic phenotype of malignant cancers has been established as a target for cancer therapy. ABT-526 and ABT-510, two peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth in mice. To guide the clinical development of these drugs, translational studies in dogs with naturally occurring cancers were initiated.